Type:60ml bot
Generic Name:Mefenamic Acid
Manufacturer:Globe Pharmaceuticals Ltd.
Price:৳40.00
Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain
Should be taken with food.
Oral Rheumatoid arthritis; Mild to moderate pain; Dental pain; Postoperative pain; Dysmenorrhoea; Osteoarthritis; Menorrhagia Adult: 250-500 mg upto 3 times daily for 3-7 days. Max. 1.5 gm total.
Oral Rheumatoid arthritis; Mild to moderate pain; Dental pain; Postoperative pain; Dysmenorrhoea; Osteoarthritis; Menorrhagia Child: >6 mth 25 mg/kg daily in divided doses for up to 7 days.
Hypersensitivity to mefenamic acid, aspirin or other NSAIDs. Patient w/ inflammatory bowel disease, active ulceration or chronic inflammation of the upper or lower GI tract, renal failure. History of asthma, urticaria, allergic-type reactions. Treatment of perioperative pain in the setting of CABG surgery, pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.
Mefenamic acid, an anthranilic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It has analgesic and antipyretic properties w/ minor anti-inflammatory activity.
Patient w/ known CV disease or risk factors for CV disease, history of GI bleeding or peptic ulceration, fluid retention or heart failure. Renal and hepatic impairment. Anemia, bronchospasm, HTN, SLE, fluid retention, bleeding diathesis. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor CBC, chemistry profile, hepatic and renal function during long-term therapy. BP should be monitored closely during initiation and throughout therapy. Lactation: contraindicated; excreted in breast milk
>10% Borderline elevations of one or more LFTs (<15%) 1-10% Abdominal pain,Anorexia,Diarrhea,Nausea,Pyrosis,Gastritis,Flatulence,Constipation,Steatorrhea,Upper GI ulcers, gross bleeding/perforation (1% of patients treated for 3-6 mth and 2-4% of those treated for 1 yo) <1% Leukopenia,Eosinophilia,Thrombocytopenic purpura,Agranulocytosis,Pancytopenia,Bone marrow hypoplasia,Renal failure (including papillary necrosis & acute interstitial nephritis),Acute interstitial nephritis has been associated with hematuria, proteinuria, & nephrotic syndrome Potentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).
Pregnancy Category: C; D in 3rd trimester or near delivery.
Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
